Genetically engineered yeast platform for biologics manufacturing

Overview

Renaissance BioScience presents a novel genetic platform leveraging the yeast strain Saccharomyces cerevisiae for biologics manufacturing. This innovative approach focuses on engineering yeast to serve as a cost-effective, scalable, and endotoxin-free microbial system for producing proteins, antibodies, and vaccine antigens. By integrating the gene of interest directly into the yeast genome, the platform eliminates the need for plasmids and antibiotic selection, addressing regulatory concerns and enhancing safety. The system ensures genetic stability, reduces contamination risks, and achieves high protein yields (>1 g/L at scale).

Technical specifications

• Microbial system: Utilizes Saccharomyces cerevisiae, a yeast strain with a proven track record in biologics production.
• Genomic integration: Multi-site integration of biologic genes ensures stable and high-level expression.
• Regulatory compliance: Avoids antibiotic resistance markers and endotoxin-producing organisms, aligning with regulatory guidelines.
• Protein secretion: Engineered yeast naturally secretes proteins into the extracellular environment, simplifying downstream processing.
• High protein yields: Capable of producing over 1 g/L at industrial scale.

Technology readiness level

Currently at Technology Readiness Level 4, this platform has undergone successful laboratory-scale demonstrations of gene integration and expression. Future validation includes optimizing fermentation processes in small-scale fed-batch bioreactors and ensuring genetic stability over 100 generations. The platform is set to comply with regulatory standards for biologic production, aiming for industrial scalability.